CALC icon

CalciMedica

2.24 USD
+0.04
1.82%
At close Mar 7, 4:00 PM EST
1 day
1.82%
5 days
-0.88%
1 month
-16.10%
3 months
-24.07%
6 months
-54.84%
Year to date
-31.91%
1 year
-49.44%
5 years
-99.03%
10 years
-99.03%
 

About: CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need. Its proprietary technology targets the inhibition of calcium release-activated calcium channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are no approved therapies.

Employees: 13

0
Funds holding %
of 7,359 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

167% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 3

80% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 5

17% more funds holding

Funds holding: 24 [Q3] → 28 (+4) [Q4]

11% more capital invested

Capital invested by funds: $13.6M [Q3] → $15M (+$1.44M) [Q4]

2.94% more ownership

Funds ownership: 28.49% [Q3] → 31.43% (+2.94%) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$13
480%
upside
Avg. target
$14.50
547%
upside
High target
$16
614%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Joseph Pantginis
18% 1-year accuracy
76 / 411 met price target
614%upside
$16
Buy
Reiterated
4 Mar 2025
LUCID CAPITAL MARKETS
Dev Prasad
33% 1-year accuracy
1 / 3 met price target
480%upside
$13
Buy
Initiated
17 Dec 2024

Financial journalist opinion

Based on 3 articles about CALC published over the past 30 days

Neutral
PRNewsWire
2 days ago
CalciMedica Secures Credit Facility for Up to $32.5 Million
$10 million funded at close extends cash runway into mid-2026 LA JOLLA, Calif. , March 5, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that the Company has entered into a credit facility with Avenue Venture Opportunities Fund II, L.P.
CalciMedica Secures Credit Facility for Up to $32.5 Million
Neutral
PRNewsWire
3 days ago
CalciMedica Presents AKI Data from a Post-Hoc Analysis of the Phase 2 CARDEA trial of Auxora™ in Severe COVID-19 Pneumonia at the 30th International AKI & CRRT Conference
62.7% relative reduction in mortality at day 30, which persisted through day 60, for patients treated with Auxora versus placebo in subset of patients in CARDEA with AKI LA JOLLA, Calif. , March 4, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that Sudarshan Hebbar, M.D.
CalciMedica Presents AKI Data from a Post-Hoc Analysis of the Phase 2 CARDEA trial of Auxora™ in Severe COVID-19 Pneumonia at the 30th International AKI & CRRT Conference
Neutral
PRNewsWire
2 weeks ago
CalciMedica Announces Upcoming Plenary Presentation at the 30th International AKI & CRRT Conference
LA JOLLA, Calif. , Feb. 19, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced a plenary presentation at the 30th International Acute Kidney Injury and Continuous Renal Replacement Therapy Conference (AKI & CRRT) being held March 3-6, 2025 in San Diego, CA.
CalciMedica Announces Upcoming Plenary Presentation at the 30th International AKI & CRRT Conference
Neutral
PRNewsWire
1 month ago
CalciMedica to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
LA JOLLA, Calif. , Feb. 3, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that Rachel Leheny, Ph.D.
CalciMedica to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Neutral
PRNewsWire
1 month ago
CalciMedica Announces Appointment of Dr. Alan Glicklich to Board of Directors
LA JOLLA, Calif., Jan. 14, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced the appointment of Alan Glicklich, M.D.
CalciMedica Announces Appointment of Dr. Alan Glicklich to Board of Directors
Neutral
PRNewsWire
3 months ago
CalciMedica to Participate in the Piper Sandler 36th Annual Healthcare Conference
LA JOLLA, Calif. , Nov. 21, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that Rachel Leheny, Ph.D.
CalciMedica to Participate in the Piper Sandler 36th Annual Healthcare Conference
Neutral
PRNewsWire
3 months ago
CalciMedica Announces Presentations at Upcoming Medical Meetings
Prof. Robert Sutton to  deliver plenary presentation on Phase 2b CARPO trial of Auxora™ in Acute Pancreatitis (AP) at American Pancreatic Association (APA) 2024 Annual Meeting Poster presentation on Phase 2b CARPO trial at Emergencies in Medicine (EIM) 2024 Meeting LA JOLLA, Calif. , Nov. 20, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced the acceptance of an abstract for plenary presentation at  the American Pancreatic Association (APA) 2024 Annual Meeting being held December 9-10 in Maui, HI, and the acceptance of an abstract for poster presentation at the Emergencies in Medicine (EIM) 2024 Meeting being held December 8-13 in Maui, HI.
CalciMedica Announces Presentations at Upcoming Medical Meetings
Neutral
PRNewsWire
3 months ago
CalciMedica Reports Third Quarter 2024 Financial Results and Provides Clinical & Corporate Updates
Additional positive data, including a win ratio analysis, announced from CARPO Phase 2b trial of Auxora™ in acute pancreatitis (AP); Company expects to be in a position to initiate Phase 3 program in 2025 Enrollment ongoing in Phase 2 KOURAGE trial in acute kidney injury (AKI) and in Phase 2 portion of CRSPA trial in asparaginase-induced pancreatic toxicity (AIPT); data from both trials expected in 2025 Following a public offering in October, the Company's cash position is expected to fund current operations into the first half of 2026 LA JOLLA, Calif. , Nov. 13, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today reported financial results for the third quarter ended September 30, 2024 and provided clinical and corporate updates.
CalciMedica Reports Third Quarter 2024 Financial Results and Provides Clinical & Corporate Updates
Neutral
PRNewsWire
3 months ago
CalciMedica Strengthens Leadership Team with Appointment of Stephen Bardin as Chief Financial Officer
LA JOLLA, Calif. , Nov. 7, 2024 /PRNewswire/ -- CalciMedica, Inc. (CalciMedica or the Company) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced the appointment of Stephen Bardin as Chief Financial Officer and the planned departure of Daniel Geffken, Interim Chief Financial Officer upon filing the Company's third quarter financial statements.
CalciMedica Strengthens Leadership Team with Appointment of Stephen Bardin as Chief Financial Officer
Neutral
PRNewsWire
4 months ago
CalciMedica Announces Pricing of Public Offering of Common Stock
LA JOLLA, Calif. , Oct. 30, 2024 /PRNewswire/ -- CalciMedica, Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium ("CRAC") channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced the pricing of an underwritten public offering of 2,720,000 shares of its common stock at a price to the public of $3.75 per share.
CalciMedica Announces Pricing of Public Offering of Common Stock
Charts implemented using Lightweight Charts™